HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.

Abstract
Four new palladium(II) complexes with the formula Pd(L)(2), where L are quinoxaline-2-carbonitrile N(1),N(4)-dioxide derivatives, were synthesized as a contribution to the chemistry and pharmacology of metal compounds with this class of pharmacologically interesting bioreductive prodrugs. Compounds were characterized by elemental, conductometric and thermogravimetric analyses, fast atom bombardment mass spectrometry (FAB-MS) and electronic, Fourier transform infrared (FTIR) and (1)H-nuclear magnetic resonance spectroscopies. The complexes were subjected to cytotoxic evaluation on V79 cells in hypoxic and aerobic conditions. In addition, a preliminary study on interaction with plasmid DNA in normoxia was performed. Complexes showed different in vitro biological behavior depending on the nature of the substituent on the quinoxaline ring. Pd(L1)(2) and Pd(L2)(2), where L1 is 3-aminoquinoxaline-2-carbonitrile N(1),N(4)-dioxide and L2 is 3-amino-6(7)-methylquinoxaline-2-carbonitrile N(1),N(4)-dioxide, showed non selective cytotoxicity, being cytotoxic either in hypoxic or in aerobic conditions. On the other hand, Pd(L3)(2), where L3 is 3-amino-6(7)-chloroquinoxaline-2-carbonitrile N(1),N(4)-dioxide, resulted in vitro more potent cytotoxin in hypoxia (P=5.0 microM) than the corresponding free ligand (P=9.0 microM) and tirapazamine (P=30.0 microM), the first bioreductive cytotoxic drug introduced into clinical trials. In addition, it showed a very good selective cytotoxicity in hypoxic conditions, being non-cytotoxic in normoxia. Its hypoxic cytotoxicity relationship value, HCR, was of the same order than those of other hypoxia selective cytotoxins (i.e., Mitomycine C, Misonidazole and the N-oxide RB90740). Interaction of the complexes with plasmid DNA in normoxia showed dose dependent ability to relax the negative supercoiled forms via different mechanisms. Pd(L2)(2) introduced a scission event in supercoiled DNA yielding the circular relaxed form. Meanwhile, both Pd(L1)(2) and Pd(L3)(2) produced the loss of negative supercoils rendering a family of topoisomers with reduced electrophoretic mobility. Pd(L3)(2) showed a more marked effect than Pd(L1)(2). Indeed, for the highest doses assayed, Pd(L3)(2) was even able to introduce positive supercoils on the plasmid DNA.
AuthorsCarolina Urquiola, Marisol Vieites, María H Torre, Mauricio Cabrera, María Laura Lavaggi, Hugo Cerecetto, Mercedes González, Adela López de Cerain, Antonio Monge, Pablo Smircich, Beatriz Garat, Dinorah Gambino
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 17 Issue 4 Pg. 1623-9 (Feb 15 2009) ISSN: 1464-3391 [Electronic] England
PMID19162490 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Ligands
  • Nitriles
  • Organometallic Compounds
  • Prodrugs
  • Quinoxalines
  • quinoxaline-2-carbonitrile
  • Palladium
  • DNA
Topics
  • Animals
  • Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
  • Cell Line
  • Cricetinae
  • Cricetulus
  • DNA (chemistry, genetics)
  • Ligands
  • Magnetic Resonance Spectroscopy
  • Nitriles (chemistry, pharmacology)
  • Organometallic Compounds (chemical synthesis, chemistry, pharmacology)
  • Palladium (chemistry, pharmacology)
  • Plasmids (chemistry, genetics)
  • Prodrugs (chemical synthesis, chemistry, pharmacology)
  • Quinoxalines (chemistry, pharmacology)
  • Spectrometry, Mass, Fast Atom Bombardment
  • Spectroscopy, Fourier Transform Infrared

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: